Compare Danaher Corporation (DHR) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Norwegian Cruise Line Holdings Ltd — how do they compare? Danaher Corporation trades at $206.84 (market cap $145.83B), while Norwegian Cruise Line Holdings Ltd trades at $18.91 (market cap $8.59B). The key difference: Danaher Corporation is far larger — about 17× Norwegian Cruise Line Holdings Ltd's market cap, and Danaher Corporation pays a 0.77% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| DHR | NCLH | |
|---|---|---|
Market Cap | $145.83B | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $26.94 |
52-Week Low | $161.91 | $14.79 |
Enterprise Value | $168.04B | $23.40B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
NCLH trades at $18.93, up 2.05% today, with a bearish technical signal but strong fundamentals including a P/E of 11.33 and net income margin of 7.49%. Recent Q2 2026 earnings beat expectations at $0.48 per share, though revenue growth faces headwinds from high costs. Analyst consensus is a buy with a $20.73 price target, but news highlights concerns over fuel expenses and demand.
The outlook is mixed: valuation metrics suggest upside potential, but risks from macroeconomic pressures and execution challenges persist. Investors may find opportunity if turnaround plans gain traction, yet volatility from operational costs and travel demand fluctuations warrants caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
